Read by QxMD icon Read

Clinical Breast Cancer

Shuning Ding, Jiayi Wu, Caijin Lin, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu
BACKGROUND: Pure mucinous breast cancer (PMBC) is a rare pathologic type of breast cancer, the prognostic factors of which have not been clearly defined. This study aimed to analyze the prognostic markers and distribution of 21-gene recurrence score (RS) in patients with PMBC. PATIENTS AND METHODS: Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a retrospective analysis of PMBC cases was conducted. Multivariate analyses were used to evaluate the indicators for prognosis and the correlations between RS and traditional clinicopathologic characteristics...
October 13, 2018: Clinical Breast Cancer
Peter A Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalves, Guy Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl A Pickett
INTRODUCTION: Trebananib, a peptide-Fc fusion protein, blocks angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. Trebananib plus trastuzumab and paclitaxel was evaluated in human epidermal growth factor receptor 2-positive breast cancer in an open-label phase 1b clinical study. PATIENTS AND METHODS: Women with human epidermal growth factor receptor 2-positive breast cancer received weekly paclitaxel (80 mg/m2 ), trastuzumab (8 mg/m2 then 6 mg/kg every 3 weeks), and intravenous trebananib (10 mg/kg or 30 mg/kg weekly) beginning week 2...
October 9, 2018: Clinical Breast Cancer
Apurva Pandey, Adam M Brufsky
No abstract text is available yet for this article.
October 4, 2018: Clinical Breast Cancer
Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Wenbin Zhou, Shui Wang
BACKGROUND: Many elderly breast cancer patients might just receive palliative local surgery, especially those with locally advanced breast cancer (LABC). However, palliative tumor removal might lead to perioperative residual tumor growth. In this study, we aimed to determine the survival effect of palliative local surgery without definitive axillary surgery for LABC in elderly patients. PATIENTS AND METHODS: Patients age 70 years or older diagnosed with T3/4M0 breast cancer, who received no surgery, mastectomy, or lumpectomy without axillary surgery, were identified in the Surveillance, Epidemiology, and End Results cancer database from 1973 to 2014...
September 27, 2018: Clinical Breast Cancer
Misako Nakagawa, Mayumi Ikeuchi, Masami Morimoto, Hirokazu Takechi, Hiroaki Toba, Takahiro Yoshida, Kazumasa Okumura, Naoki Hino, Aya Nishisho, Akira Tangoku
BACKGROUND: To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-1+DOC) were evaluated. PATIENTS AND METHODS: Patients were treated with docetaxel (40 mg/m2 intravenously on day 1) and S-1 (40 mg/m2 orally twice per day on days 1-14) every 3 weeks for 4 cycles. In accord with the Response Evaluation Criteria In Solid Tumors version 1...
September 27, 2018: Clinical Breast Cancer
Robert Kowalczyk, Krzysztof Nowosielski, Ida Cedrych, Marek Krzystanek, Iwona Glogowska, Joanna Streb, Jakub Kucharz, Zbigniew Lew-Starowicz
INTRODUCTION: Knowing the important factors influencing sexual function and body image might facilitate the recovery process of breast cancer survivors. Surgery type, relationship quality, and partner support might be modified to create a space for psychosexual intervention. PATIENTS AND METHODS: This retrospective questionnaire-based study was performed on 128 women aged 18 to 65 years who were free of disease at time of study entry and who underwent surgical treatment for breast cancer...
September 21, 2018: Clinical Breast Cancer
Olfat G Shaker, Mahmoud A Senousy
BACKGROUND: Genetic susceptibility for breast cancer (BC) is still poorly understood. A combination of multiple low-penetrant alleles of cancer-related genes and gene-gene interactions (epistasis) contributes to BC risk. Genetic variants in receptor activator of nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), chitinase-3-like protein 1 (CHI3L1), and vitamin D receptor (VDR) genes are implicated in breast carcinogenesis; however, the influence of their epistatic effects on BC susceptibility has not yet been studied...
September 19, 2018: Clinical Breast Cancer
Kamila Pires de Carvalho, Mariana Tavares Miranda Lima, Fernanda Silva Mazzutti, Isis Danyelle Dias Custódio, Paula Philbert Lajolo Canto, Carlos Eduardo Paiva, Yara Cristina de Paiva Maia
PURPOSE: To study the use of functional capacity (FC) level and duration of aromatase inhibitor (AI) therapy with adiposity parameters in women with breast cancer. PATIENTS AND METHODS: FC was evaluated through the Health Assessment Questionnaire, which was assessed by classification and divided into 3 groups: G1 = mild to moderate difficulty, G2 = moderate to severe disability, and G3 = severe or very severe disability. Body mass, height, and waist circumference (WC) were measured, and body mass index (BMI) was calculated...
September 13, 2018: Clinical Breast Cancer
Geoffrey Alan Watson, Oana Deac, Razia Aslam, Richard O'Dwyer, Antonia Tierney, Sue Sukor, John Kennedy
BACKGROUND: The cyclin-dependent kinase 4/6 inhibitor palbociclib has emerged as a novel therapeutic agent in metastatic breast cancer. Neutropenia is commonly observed, and thus stringent treatment guidelines regarding complete blood count (CBC) monitoring have been developed. The aim of this study was to provide a real-world experience of the toxicities associated with palbociclib therapy and to evaluate compliance with CBC monitoring. PATIENTS AND METHODS: We performed a retrospective single-center audit of hormone receptor-positive metastatic breast cancer patients treated with palbociclib over a 6-month period in an Irish tertiary referral hospital...
September 8, 2018: Clinical Breast Cancer
William Hsu, Xinkai Zhou, Antonia Petruse, Ngan Chau, Stephanie Lee-Felker, Anne Hoyt, Neil Wenger, David Elashoff, Arash Naeim
PURPOSE: To analyze women with suspicious findings (assessed as Breast Imaging Reporting and Data System [BI-RADS] 4), examining the value of clinical and imaging predictors in predicting cancer diagnosis. PATIENTS AND METHODS: A set of 2138 examinations (1978 women) given a BI-RADS 4 with matching pathology results were analyzed. Predictors such as patient demographics, clinical risk factors, and imaging-derived features such as BI-RADS assessment and qualitative breast density were considered...
September 5, 2018: Clinical Breast Cancer
Semir Vranic, Juan Palazzo, Souzan Sanati, Elena Florento, Elma Contreras, Joanne Xiu, Jeffrey Swensen, Zoran Gatalica
INTRODUCTION: Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific biomarkers were recently investigated in the NEC of lung and in other types of breast carcinoma, which may provide guidance to their feasibility in breast NEC. MATERIALS AND METHODS: Twenty breast NECs were profiled for biomarkers of therapy including antibody-drug conjugates (DLL3, TROP-2, and FOLR1), histone deacetylase (H3K36Me3) inhibitors, tropomyosin receptor kinases (NTRK1/2/3 gene fusions) targeted inhibitors, alkylating agents (MGMT), and immune checkpoint inhibitors (PD-L1, TMB, and MSI) using immunohistochemistry and DNA/RNA next-generation sequencing assays...
September 5, 2018: Clinical Breast Cancer
Sharon F McGee, Lisa Vandermeer, Sasha Mazzarello, Marta Sienkiewicz, Carol Stober, Brian Hutton, Dean Fergusson, John Hilton, Jean-Michel Caudrelier, Phillip Blanchette, Mark Clemons
BACKGROUND: Patients can start endocrine therapy before, concurrently with, or sequentially after radiotherapy. The optimal timing of starting adjuvant endocrine therapy is unknown. This survey was performed to evaluate physician recommendations. METHODS: Canadian oncologists were surveyed to evaluate institutional and personal practices regarding the prescription of adjuvant endocrine therapy and radiotherapy. Perspectives regarding the design of a clinical trial to compare concurrent versus sequential therapy, and the optimum end points for such a trial, were also sought...
September 4, 2018: Clinical Breast Cancer
Soufiane Berhili, Asmae Ouabdelmoumen, Ali Sbai, Tayeb Kebdani, Noureddine Benjaafar, Loubna Mezouar
INTRODUCTION: The present study aimed to detect the factors associated with psychological distress (PD) in young Moroccan patients with breast cancer, with a special focus on the type of surgical procedure. PATIENTS AND METHODS: We collected social, demographic, and clinical data from female patients, aged < 45 years, with localized stage breast cancer who had undergone either radical mastectomy or conservative surgery and for whom adjuvant chemotherapy was indicated...
August 31, 2018: Clinical Breast Cancer
Babita Panigrahi, Susan C Harvey, Lisa A Mullen, Eniola Falomo, Philip Di Carlo, Bonmyong Lee, Kelly S Myers
BACKGROUND: There are few data regarding the use and outcomes of Breast Imaging Reporting and Data System (BI-RADS) 3 assessment on breast magnetic resonance imaging (MRI). The aim of this study was to describe the imaging findings prompting a BI-RADS 3 assessment and to report their outcomes, including the timing of follow-up examinations. PATIENTS AND METHODS: We performed a retrospective study evaluating 199 breast lesions in 186 patients who were assigned a BI-RADS 3 assessment on breast MRI over a 5-year period...
August 31, 2018: Clinical Breast Cancer
Jie Xie, Yan Yang, Jiali Sun, Zhi Jiao, Haozheng Zhang, Jie Chen
PURPOSE: Six-transmembrane epithelial antigen of prostate 1 (STEAP1) is a cell surface antigen overexpressed in multiple cancers and is associated with malignancy and disease prognosis. The aims of this study were to evaluate STEAP1 expression in breast cancer and to determine the mechanisms involved. METHODS: STEAP1 expression was compared in normal breast tissue (n = 40), benign fibroadenoma (n = 52), and primary breast cancer (n = 211) using immunohistochemistry...
August 30, 2018: Clinical Breast Cancer
Won Kyung Cho, Won Park, Doo Ho Choi, Yong Bae Kim, Jin Ho Kim, Su Ssan Kim, Kyubo Kim, Jin Hee Kim, Sung Ja Ahn, Sun Young Lee, Jeongshim Lee, Sang-Won Kim, Jeanny Kwon, Ki Jung Ahn
BACKGROUND: Given the lack of established indications for elective nodal irradiation (ENI) in ypN0 patients after neoadjuvant chemotherapy (NAC) and breast-conserving surgery (BCS), we set out to investigate the role of ENI in ypN0 patients according to subtype and pathologic complete remission (pCR) status. PATIENTS AND METHODS: We analyzed 261 patients who received NAC followed by BCS and adjuvant radiotherapy in 13 institutions of the Korean Radiation Oncology Group from 2005 to 2011...
August 28, 2018: Clinical Breast Cancer
Naoki Hayashi, Hiroko Tsunoda, Maki Namura, Tomohiro Ochi, Koyu Suzuki, Hideko Yamauchi, Seigo Nakamura
BACKGROUND: Magnetic resonance imaging (MRI) or ultrasonography (US) alone is limited in the ability to predict the pathologic complete response (pCR) accurately after neoadjuvant chemotherapy (NAC). The aim of the present study was to predict the pCR using MRI combined with second-look US in primary breast cancer patients. MATERIALS AND METHODS: A total of 1274 consecutive primary breast cancer patients who were examined by MRI and second-look US before and after NAC and had undergone breast-conserving surgery from 2004 to 2014 were included...
August 24, 2018: Clinical Breast Cancer
Denise A Yardley, Dianna Shipley, John Zubkus, Gail L Wright, Patrick J Ward, Aruna Mani, Mythili Shastry, Lindsey Finney, Laura DeBusk, John D Hainsworth
BACKGROUND: Eribulin mesylate is a non-taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epithelial mesenchymal transition and tumor vascular remodeling. The present study compared the safety and efficacy of eribulin plus cyclophosphamide (ErC) to docetaxel plus cyclophosphamide (TC) as neoadjuvant therapy for operable HER2- breast cancer...
August 23, 2018: Clinical Breast Cancer
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, Matthieu Faron, Mahasti Saghatchian, Michael Grynberg, Marc Spielmann, Paul Kerbrat, Henri Roché, Veronique Lorgis, Thomas Bachelot, Mario Campone, Christelle Levy, Anthony Gonçalves, Anne Lesur, Corinne Veyret, Laurence Vanlemmens, Jerome Lemonnier, Suzette Delaloge
BACKGROUND: The likelihood of menses recovery varies greatly in premenopausal patients receiving adjuvant chemotherapy for breast cancer. Quantifying this probability for each patient could better inform the chemotherapy discussion and individualize fertility counseling. We performed a pooled analysis of the PACS04 and PACS05 adjuvant randomized trials to develop a nomogram to estimate the probability of menses recovery at 3, 6, and 18 months after the end of adjuvant chemotherapy. PATIENTS AND METHODS: Women who were premenopausal and aged ≤ 50 years at randomization in the PACS04 and PACS05 trials were included in the present analysis...
August 23, 2018: Clinical Breast Cancer
Michael Yan, Mohamed Ahmed Abdi, Conrad Falkson
Optimal regional management in breast cancer patients has yet to be established. In patients who are clinically node-negative, but sentinel lymph node biopsy (SLNB)-positive, the treatment paradigm has shifted toward the de-escalation of further axillary management. In patients with 2 or fewer positive sentinel nodes, the standard of practice has shifted away from complete axillary lymph node dissection (ALND) as a result of the ACOSOG Z0011 trial. The role of regional nodal irradiation (RNI) to the axilla, supraclavicular and internal mammary regions has also been investigated in the setting of positive SLNB in trials such as the MA20 and EORTC 22922...
August 22, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"